Bayer's healthcare sales up 5%
This article was originally published in Clinica
Germany-based Bayer reported healthcare sales, which include diagnostics, of DM 5,873 million ($3,970 million) in the first half of 1996, up 5% on the same period last year. Sales in the Agfa division, which includes medical imaging systems, were up 11% to DM 3,709 million. Bayer's total sales rose 7% to DM 24,797 million and pre-tax earnings were DM 2,720 million, 13% up on the previous year. The company expects a sales increase of 6% and pre-tax earnings of 10% for the full year.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.